Fairfield, Conn., September 15, 2011 – (NYSE: GE) – GE and
leading healthcare and financial partners today launched a new
healthymagination initiative aimed at accelerating cancer innovation and
improving care for 10 million cancer patients around the world by 2020.
The campaign is founded on GEs integrated portfolio, which is uniquely
positioned to drive game-changing impact in oncology and a leap forward for
individualized cancer care.

GE CEO and Chairman Jeff Immelt and several venture capital
partners today announced a healthymagination open innovation Challenge to fund
promising ideas to improve breast cancer diagnostics. To learn more about this
initiative, visit www.healthymagination.com.
Immelt also said that GE will invest $1 billion over the next five years on
R&D programs to expand its suite of advanced
technologies and solutions for cancer detection and treatment, beginning with
breast cancer.

"We envision a day when cancer is no longer a deadly
disease," said Jeff Immelt, CEO and Chairman, GE. "When you add our
cutting edge cancer detection technologies to the innovative ideas of our new
partners, its a powerful formula for tackling cancer and helping doctors and
researchers improve care."

Nancy Brinker, founder and CEO, Susan G. Komen for the Cure
said, "Extraordinary things can happen when you apply imagination to solve big
problems. This initiative brings new innovation, commitment and significant
resources to the table, and were very excited about its potential to help us
end suffering and death, on a global scale, from the most commonly diagnosed
cancer in women."

Open Innovation to Save Lives

GE announced today a $100 million global open innovation challenge that seeks
to identify and bring to market ideas that advance breast cancer diagnostics.
The goal is to help health care professionals better understand tumors
associated with triple negative cancer, a type of cancer that is less
responsive to standard treatments and is typically more aggressive, as well as
the molecular similarities between breast cancer and other solid tumors,
improving early detection, allowing for more accurate diagnoses and ultimately
helping doctors make the best possible treatment decisions based on each
patients unique cancer.

The Challenge, open immediately for entries at www.healthymagination.com/challenge,
was launched in collaboration with leading venture capital firms Kleiner
Perkins Caufield & Byers, Venrock, Mohr Davidow and MPM Capital. The
effort will also feature a special focus on data, in partnership with OReilly
Media, whose CEO & founder, Tim OReilly is a preeminent advocate for using
data science to spur innovation.

Risa Stack, partner at Kleiner, Perkins, Caufield &
Byers and GE healthymagination Challenge judge said, "Based on our work in
healthcare, we think that there is great opportunity to impact cancer care with
new technology in the next 10 years. As we saw through the success of the
ecomagination Challenge, innovation can be transformational and good ideas that
drive change can come from anywhere. We look forward to once again partnering
with GE on the healthymagination Challenge to help shape a new age in patient
care."

Challenge entrants will be evaluated by a committee of
representatives from GE and venture capital partner firms. A separate,
independent judging panel that includes GE executives, venture capital partners
and several leading healthcare luminaries - such as former U.S. FDA
Commissioner and National Cancer Institute Director, Dr. Andrew Von Eschenbach;
Professor of Surgery and Director of the University of Michigan Breast Care
Center, Dr. Lisa Newman; and cancer medicine specialist and Imperial Colleges
professor of cancer medicine, Dr. Justin Stebbing - will select the recipients
of the $100,000 innovation seed grants. To view the full terms and conditions,
visit healthymagination.com/challenge.
Winners will be announced in the first quarter of 2012.

Andrew von Eschenbach, GE healthymagination Challenge judge
and healthymagination advisory board member said, "Scientific discovery and
advances in technology have induced a tipping point in our understanding of
cancer. To design and deliver integrated solutions for individual patients, we
can no longer work in silos. We must combine our assets for diagnosis and
therapy working in concert with partners across the private sector, government,
NGOs and academia to create the right treatment for the right patient to
achieve the right outcome, eliminating suffering and death from cancer."

GE is also investing in the development of a first-in-kind
"super database," which will consolidate clinical, pathology, therapy and
outcomes data in one place to enable analysis and further accelerate
innovation. This super database will be available in collaboration with leading
cancer research, NGO and government organizations, starting with relevant cancer
data from GEs Medical Quality Improvement Consortium; Clarient, a GE
Healthcare Company; The Premier healthcare alliance; and the U. S. Department
of Health & Human Services.

New Technologies to Improve Screening and Diagnosis

GE will launch new innovations that improve screening and breast cancer
diagnosis, and help doctors ensure patients receive the right therapy for their
tumor type.

John Dineen, president and CEO, GE Healthcare said, "Cancer
is a complex disease and because every patients cancer is different,
oncologists need advanced tools to â€˜fingerprint individual cancerous
tumors. GE Healthcare continually breaks new ground in advanced diagnostic
and molecular imaging equipment, partnering with hospitals and physicians to
better manage patients throughout the cancer journey. Today and as we look to
the future, we will continue to help doctors characterize cancer at the
cellular level. This empowers them with the targeted information they need to
prescribe the most accurate and effective therapy for their patient the first
time."

GE announced SenoCase™, a breakthrough new ultra-portable mammography
device concept that will take a traditional digital mammography system and
miniaturize it into an affordable portable unit the size of a large suitcase.
This concept has the potential to transform access to breast health screenings
for millions of women around the world, bringing life-saving technology to
women where they live.

GE also previewed the game-changing SenoBright™, Contrast
Enhanced Spectral Mammography (CESM), a breast screening technique that will
enable more precise identification of breast cancer incidence for over one
million women by 2020. SenoBrights exclusive imaging technique, which combines
digital mammography, low-and high-level x-rays and a common contrast agent,
better identifies incidence of cancer, and helps clinicians better select
patients requiring biopsy. SenoBright will result in lower costs by reducing
unneeded procedures and improving a doctors ability to appropriately treat
patients. SenoBright is currently 510k clearance pending at the U.S. FDA, and
not available for sale in the United
States. Outside the U.S., SenoBright has been installed in 17 care
centers across Europe and Asia.

GEs commitment to new oncology solutions extends through
the full cancer care continuum. Among the advanced technologies that GE
scientists are working on is a new positron emission tomography (PET)
tracer. The goal of this tracer is to help doctors evaluate whether
particular cancer treatments are working very early in the course of therapy,
by measuring new blood vessel formation in tumors.

Collaboration to Expand Global Access to Care

GE today announced a three-year partnership with Susan. G Komen for the Cure to
forge first-in-kind programs that bring the latest breast cancer technologies
to more women in the United
States and around the world. Initially,
these programs will run in Wyoming, Saudi Arabia and China.

Wyoming: By taking an
innovative approach to mobile mammography and applying a digital twist to
appointment bookings, GE is partnering with a number of in-state organizations
to help Wyoming address the challenges
associated with being one of the most rural states in the U.S.

Saudi Arabia:
GE and the Kingdom
of Saudi Arabias
Ministry of Health established a mutual partnership aimed at increasing access
to breast cancer screening. GE will develop and deploy two mobile
screening units in Riyadh
City with the goal of
screening 10,000 women within the first 12 months with a plan to start in
October 2011. Its also reaching out to leading universities to launch an
open innovation challenge for Saudi women in an effort to identify sustainable
methods for improving breast cancer screening in the country.

China: GE
and partners will launch a broad outreach program later this year in the Guangdong Province aimed at raising awareness of
and compliance with breast cancer screening procedures. The program will
develop a local model to improve education and breast screening in rural areas.

GE will publicly track progress against its cancer
commitment on healthymagination.com.

To learn more, visit www.healthymagination.com. Follow us on Twitter @GEHealthy or visit us on Facebook at
facebook.com/healthymagination.

About GE

GE (NYSE: GE) is a diversified infrastructure, finance company taking on the
worlds toughest challenges. From aviation and power generation to financial
services, healthcare solutions, oil and gas and rail, GE operates in more than
100 countries and employs about 300,000 people worldwide. For more information,
visit the company's Web site at www.ge.com.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that
are shaping a new age of patient care. Our broad expertise in medical imaging
and information technologies, medical diagnostics, patient monitoring systems, drug
discovery, biopharmaceutical manufacturing technologies, performance
improvement and performance solutions services help our customers to deliver
better care to more people around the world at a lower cost. In addition, we
partner with healthcare leader, striving to leverage the global policy change
necessary to implement a successful shift to sustainable healthcare systems.
Headquartered in the United
Kingdom, GE Healthcare is a unit of General
Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed
to serving healthcare professionals and their patients in more than 100
countries. For more information about GE Healthcare, visit www.gehealthcare.com.

About GEs healthymagination Initiative

Launched in May 2009, GEs healthymagination initiative is focused on four
critical needs: low-cost technology; healthcare IT; innovation accessible to
all; and consumer-driven healthcare. GE has committed that by 2015 it
will:

Invest $3 billion in research and development to launch at
least 100 innovations that will help deliver better care to more people at
lower cost.

Provide $2 billion in financing and $1 billion in technology
to bring healthcare information technology to rural and underserved areas.

Reduce the cost of procedures that use GE technologies and services
by 15 percent and develop products tailored to underserved regions of the
world.

Reach 100 million more people every year with services and
technologies essential for health.